Monopar and NorthStar Update Collaboration Agreement

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company, and NorthStar Medical Radioisotopes, LLC, a leading producer of medical radioisotopes, have announced a significant expansion and amendment to their existing collaboration. This agreement, established on June 11, 2024, outlines a long-term supply arrangement where NorthStar will provide Monopar with actinium-225 (Ac-225), a powerful radioisotope essential for Monopar’s therapeutic developments.

The revised collaboration capitalizes on NorthStar’s substantial investment in Ac-225 manufacturing and Monopar’s promising preclinical results with the same isotope in their lead MNPR-101 radiopharmaceutical program. This amendment not only extends the supply agreement but also addresses economic terms and intellectual property rights related to the MNPR-101 platform. Monopar has now acquired complete ownership of these rights from NorthStar, while both entities will jointly hold the patent application for using PCTA as a linker with Ac-225. This linker has demonstrated superior binding and yield compared to the current industry standard, DOTA.

Chandler Robinson, MD, CEO of Monopar, expressed enthusiasm for the enhanced collaboration, highlighting its potential to support current and future development and commercialization of Monopar’s products. On the other side, Frank Scholz, PhD, CEO of NorthStar, emphasized NorthStar’s readiness to become the first commercial-scale producer of non-carrier-added (n.c.a.) Ac-225 and its commitment to advancing Monopar’s innovative MNPR-101 platform aimed at treating aggressive cancers.

Monopar Therapeutics is dedicated to creating groundbreaking treatments for cancer patients. Their pipeline includes MNPR-101-Zr, in Phase 1 for imaging advanced cancers, and MNPR-101, in late preclinical stages as a radio-immuno-therapeutic for advanced cancer treatment.

NorthStar Medical Radioisotopes, known for its leadership in radiopharmaceutical innovation, is focused on producing commercially viable radioisotopes for cancer detection and treatment. NorthStar’s unique production technology and robust management team position it as a pioneer in the radiopharmaceutical therapy sector. The company also offers Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services, assisting biopharmaceutical firms in accelerating their development and commercialization efforts.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!